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CLINICAL INVESTIGATION
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Effect of hemodialysis and peritoneal dialysis on aztreonam pharmaco-
kinetics. Aztreonam, a new monobactam, will be widely used because
of its broad aerobic gram-negative bacterial coverage and its apparent
low risk of allergic phenomena in penicillin/cephalosporin-sensitive
patients. We examined aztreonam kinetics in patients during hemodial-
ysis and in the interdialytic period and in patients on continuous
ambulatory peritoneal dialysis (CAPD), and related aztreonam to urea
clearance (CL). In hemodialysis patients, aztreonam serum half-life was
7.9 hr between and 2.7 hr during dialysis sessions. CLr,.,m, CLrenai, and
CLot5er were 24.4, 0.5, and 23.9 mI/mm, respectively, during the
interdialytic period. Four hours of dialysis removed 38.2% (range, 27 to
58%) of antibiotic. CL of aztreonam by hemodialysis was 36.6 to 43.2
mL/min, 50 to 77% greater than interdialytic CL. CL of urea by
hemodialysis was 112.4 to 155.6 mI/mm; CLaztreorn,m/CLurea ratio was
0.28 to 0.33 during the hemodialysis sessions. During CAPD, aztreonam
serum half-life after intravenous dosing was 7.1 hr; dialysate recovery,
9.7% of the dose; CLserum, CLrer,ai, CLp.ritonai diaIysis and CLother were
23.8, 0.5, 2.1, and 21.3 mI/mm, respectively. CLurea by CAPD was 6.5
mI/mm. Thus, CLaztreo,,am during CAPD was 32% of CLurea. Aztreonam
was detectable in dialysate at 48 hr (eight exchanges) after peritoneal
administration in the first exchange. Hemodialysis and CAPD patients
given aztreonam treatment should receive the standard dose of az-
treonam as a loading dose, followed by one-fourth the loading dose at
standard dose intervals. Hemodialysis patients should receive a supple-
mental dose equal to half their usual maintenance dose immediately
after each dialysis session. For CAPD patients with peritonitis due to
susceptible organisms, a 1-g iv. loading dose followed by a 0.5-g i.p.
dose every 6 hr is suggested. In any individual patient undergo-
ing hemodialysis or CAPD, the relationship between CLurea and
CLaztreonam should allow appropriate antibiotic dose adjustment.
Effet de l'hémodialyse et de Ia dialyse péritoneale sur Ia pharmacoci-
netique de l'aztréonam. L'aztréonam, une nouvelle monobactame, sera
largement employee en raison de son vaste spectre bactérien gram-
negatif aérobie et de son faible risque apparent de phénomènes aller-
giques chez les malades sensibles a Ia penicilline/céphalosporine. Nous
avons examine La cinétique de l'aztréonam chez des malades pendant
l'hémodialyse et durant La période interdialytique, et chez des malades
en dialyse péritonéale continue ambulatoire (CAPD) et nous avons relié
la clearance de l'aztréonam a celle de l'urée (CL). Chez les hémodia-
lysés, La demi-vie sérique de l'aztréonam était de 7,9 hr entre et 2,7 hr
pendant les seances de dialyse. CLserum, CLrer,0i0, et CL,utres étaient de
24,4, 0,5, et 23,9 mI/mm, respectivement pendant La pCriode interdialy-
tique. Quatre heures de dialyse epuraient 38,2% (de 27 a 58%) de
l'antibiotique. CL de l'aztréonarn par l'hemodialyse Ctait de 36,6 a43,2
ml/min, 50 a 77% plus Clevée que CL interdialytique. CL de l'urée par
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hemodialyse était de 112,4 a 155,6 mI/mm; le rapport CLaztréonam/CLurt
était de 0,28 a 0,33 pendant les seances d'hemodialyse. Au cours de Ia
CAPD, Ia demi-vie sérique de l'aztréonam après administration iv.
était de 7,1 hr; La rédupération dans le dialysat de 9,7% de Ia dose;
CLserum, CLrenaie, CLdia!yse peritonéale. et CLautre. étaient de 23,8, 0,5,
2,1, et 21,3 mI/mm respectivement. CLuree par CAPD était de 6,5
mI/mm. Ainsi, CLaztréonaa, pendant La CAPD était de 32% de CLuree.
L'aztréonam etait detectable dans le dialysat 48 hr (nuit échanges) après
administration peritonéaLe mrs du premier echange. Les malades en
hemodialyse ou CAPD traités par l'aztréonam devraient recevoir Ia
dose standard d'aztréonam comme dose de charge suivie par un quart
de Ia dose de charge aux intervalles de Ia dose standard. Les hémodia-
lysés devraient recevoir une dose supplémentaire egale a Ia moitié de
leur dose d'entretien habituelle immédiatement après chaque séance de
dialyse. Chez les malades en CAPD atteints de péritonite par des
organismes sensibles, il est suggére une dose de charge de L-g iv.,
suivie de 0,5-g par voie intrapdritonéale toutes les 6 hr. Chez tout
malade en hemodialyse ou CAPD individuellement, Ia relation entre
CLuree et CLaztronam devrait permettre l'ajustement posologique appro-
prié de I'antibiotique.
Aztreonam (formerly azthreonam or SQ 26,776) is a unique
synthetic beta-lactam antibiotic of the monobactam class [1]. It
has good in vitro activity against many aerobic gram-negative
bacilli, including several aminoglycoside-resistant strains [2—41.
Infections due to these organisms are often seen in chronically
ill patients, including those with endstage renal disease (ESRD).
Previous studies in normal subjects have shown that the serum
half-life is about 1.7 hr; approximately 65% of a parenteral
aztreonam dose is eliminated unchanged in the urine within 24
hr of administration [5, 6]. Aztreonam clearance correlates well
with creatinine clearance; its elimination progressively slows as
renal function decreases [7]. In early clinical trials, aztreonam,
administered intravenously at doses of 1 to 8 g/day, was
efficacious in the therapy of various systemic infections due to
susceptible organisms while displaying a safety profile similar
to older beta-lactam antibiotics (data on file, The Squibb
Institute for Medical Research). In addition, the proper use of
this antibiotic requires an understanding of hemodialysis effects
on the distribution and elimination of the drug. Therefore, the
purposes of the present study done with ESRD patients during
chronic hemodialysis or continuous ambulatory peritoneal dial-
ysis (CAPD) were to (1) compare the pharmacokinetics of
aztreonam during an interdialytic period and during hemodialy-
sis, (2) determine the kinetics of peritoneal transfer of az-
treonam during CAPD, (3) compare aztreonam and urea clear-
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Table 1. Patient characteristics
Patient no.
Age
years Sex
Height
cm
Weight
cm Etiology of ESRD
Hemodialysis
Ia 55 M 42.1 Nephrolithiasis
2 29 F 162 50.1 Chronic glomerulonephritis
3 40 M 179 91.0 Hypertensive nephrosclerosis
4 44 M 180 67.0 Unknown
5 42 M 180 72.0 Neurogenic bladder/chronic phelonephritis
6 20 F 162 48.0 Chronic pyelonephritis
Mean SD 38 12 173 10 61.7 18.4
CAPD
7 26 M 167 56.1 Membranoproliferative glomerulonephritis8' 64 M 75.9 Diabetic nephropathy
9 57 M 165 69.6 Chronic glomerulonephritis
10 41 F 153 68.7 Alport syndrome
11 47 M 183 75.1 Chronic pyelonephritis
12 33 M 159 69.5 Familial nephritis
Mean SD 45 14 165 11 69.2 71
a The patient had bilateral lower extremity amputations, making an entry in the Height category unnecessary.
ances during hemodialysis and CAPD, and (4) obtain single-
dose safety data for aztreonam in ESRD patients.
Methods
Drug. The Squibb Institute for Medical Research, Princeton,
New Jersey, provided sterile vials containing a sterile powder
blend of aztreonam (1 g) and L-arginine (0.7 g) as a buffering
agent for reconstitution with 10 ml of sterile water prior to the
injection.
Volunteers. Six hemodialysis patients aged 20 to 55 years and
six CAPD patients aged 26 to 64 years, all with documented
ESRD, gave written informed consent to participate in the
study, which was approved by the Human Investigation Com-
mittee of the University of Virginia School of Medicine, Char-
lottesville, Virginia. All CAPD patients were well trained in the
procedure, free of abdominal discomfort, without evidence of
acute or chronic peritonitis, and with clear peritoneal fluid at
the time of entry into the study. Patient characteristics are
presented in Table 1. Patients with a history of penicillin or
cephalosporin allergy, alcohol or drug abuse, abnormal hepatic
function, history of positive hepatitis B surface antigen, abnor-
mal cardiovascular function, red cell glucose-6-phosphate dehy-
drogenase (G-6-PD) deficiency, or previous exposure to az-
treonam were excluded from the study. Each patient was
admitted to the Clinical Research Center of the University of
Virginia Medical Center on the day prior to the study. The
following investigations were performed before and after the
study: complete medical history and physical examination, 12-
lead electrocardiogram, urinalysis (if available), complete bio-
chemical profile, hematologic profile, and 24-hr creatinine
clearance (for patients who were not anuric).
Study procedure: (1) Hemodialysis. Each patient received a
single l-g i.v. dose of aztreonam on two occasions separated by
1 week according to a randomized crossover design. This
allowed collection of data both during a hemodialysis session
and an interdialytic period. On day 1, following an 8-hr fast,
pre-study laboratory samples were obtained. One gram of
aztreonam was administered intravenously over 2 mm. The
patients fasted for 2 hr after drug administration. On the day
that the patient received hemodialysis, blood samples for
aztreonam levels were collected at the following times: pre-
infusion (just prior to aztreonam dose) and at 1, 2, 3,4,and 5 hr
after aztreonam dosing. Hemodialysis was begun exactly 1 hr
after dosing according to a protocol outlined below. Paired
arterial and venous blood samples were drawn while the patient
was on dialysis for analysis of aztreonam and urea. Cumulative
dialysate collections were made for the following time intervals:
1 to 2, 2 to 3, 3 to 4, and 4 to 5 hr after aztreonam administra-
tion. Each dialysate collection was weighed and a 10-mi aliquot
of the dialysate collection was drawn for urea and aztreonam
determinations. In addition, a 10-mi spot sample of effluent
dialysate was obtained at the following times: 1, 2, 3, 4, and 5
hr. Each spot sample was divided into 5-mi aliquots for urea and
aztreonam determinations.
Each patient was also studied during an interdialytic period
separated from the dialysis study by 7 days. The pre-study
preparation was the same as for the hemodialysis study. Fol-
lowing intravenous administration of the aztreonam, blood
samples for aztreonam levels were collected at 10, 20, and 30
mm, and 1, 2, 6, 12, 24, 36, and 48 hr after drug administration.
Urine samples were obtained when possible in 12-hr cumulative
collections for 48 hr after aztreonam administration.
All patients underwent 4 hr of hemodialysis during this study
in the Renal Unit of the University of Virginia Hospital. The
dialysate delivery system was the single pass system (AK-b,
Gambro, Inc., Newport News, Virginia). The artificial kidney
was the Gambro Lundia Plate with a pore diameter of 11.5 s
and effective membrane area of 1.0 m2. Blood flow rate was 200
mllmin, except for patient 5 (250 mllmin). Dialysate flow rate
was 500 mi/mm. Au patients were dialyzed by the two-needle
puncture technique. Systemic anticoagulation and the degree of
ultrafiltration were adjusted according to previously identified
guidelines for each patient.
(2) CAPD. Each patient received a single l-g dose of az-
treonam on two occasions separated by 1 week according to a
randomized crossover design. All the patients were given a
physical examination to exclude peritonitis just prior to receiv-
ing each dose of aztreonam. The overnight dialysate was
completely drained and examined to ensure that it was clear and
that peritonitis (chemical or bacterial) was not present. Each
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(1 — H)Qb(C5 — C50)
CLhd.B n
'—Si
Ahd, I — 5CLhdc =
serum AUChdl_5
patient received on separate occasions a single l-g dose of Curve stripping of C versus t data and optimization of the
aztreonam infused over 2 mm and a single 1-g dose of az- coefficients R, S, a, and /3 by nonlinear regression analysis were
treonam in 2 liters of peritoneal dialysis fluid instilled over 10 performed using the computer programs AUTOAN and NON-
mm. The composition of the peritoneal dialysis fluid was 132 UN [101 on an IBM 370 digital computer. All serum data were
mEq/liter Na, 3.5 mEq/liter Ca, 1.5 mEq/liter Mg, 102 mEq/liter weighted according to their reciprocals for computer analysis.
Cl, and 35 mEq/liter lactate. Aztreonam was stable in this The relationships between the coefficients R and S and the
dialysis fluid under the conditions of this study; the potential for coefficients A and B for this model were
aztreonam in a concentrated solution to adsorb to peritoneal
dialysis equipment (catheter, dialysate bag) was judged to be
insignificant (data on file, The Squibb Institute).
After intravenous administration of aztreonam, venous blood
A = (RaT)I[l — exp(—aT)]
B = (S/3T)/[1 — exp(—13T)1
was collected at the same time intervals described for hemodial-
ysis patients in the interdialytic phase. Each l0-ml blood sample where a and /3 were hybrid rate constants and T was the
was divided for analysis of aztreonam and urea concentrations, duration of the infusion. Volume of distribution for the central
Total urine collections were made in the manner described for compartment was expressed as V1 = Dose/[(A + B)Wl, where
hemodialysis patients. W was body weight in kilograms. The volume of distribution
Peritoneal dialysis fluid was instilled into the patients' perito- based on the area under the serum concentration-time curve
neal cavity via gravity over 10 mm prior to administration of was expressed as Dosel[/3W(AIa) + (B113)1. The volume of
aztreonam at time zero. The patients then moved around freely distribution at steady-state was expressed as = V1[l +
to allow proper mixing of the dialysate and remained ambula- (k121k21)j, where the intercompartmental rate constants were
tory during the next 12 to 18 hr. A total of eight exchanges were expressed as k21 = (A/3 + Ba)I(A + B) and k12 = a + /3 — k21 —
made at 6-hr intervals to cover 48 hr. The volume of dialysate k10. In addition, the rate constant for elimination from the
fluid drained at the end of each exchange was accurately central compartment was expressed as k10 = a/3/k21. The
measured and recorded. Dialysate samples (5 ml) were collect- volume of distribution for the peripheral compartment was
ed aseptically just prior to the intravenous dose of aztreonam, represented by V2 = V55 — V1. Half-lives for the distribution
at the same times that blood was obtained. Samples obtained at and elimination phases of the serum concentration-time data
the 6-hr intervals were drawn immediately prior to the next were expressed as t112a = (In 2)/a and t112/3 = (ln 2)113,
exchange of peritoneal fluid. The times and pattern for obtain- respectively. Serum clearance was expressed as CLserum =
ing blood, peritoneal, and urine samples were the same whether V1k10/W. Renal clearance was calculated by multiplying serum
the aztreonam was administered intravenously or clearance by the fraction of dose recovered in the urine.-
intraperitoneally. Clearance of aztreonam by routes other than renal elimination
All serum, urine and dialysate samples were transferred to was computed as the difference between serum and renal
polypropylene tubes, labeled and stored at 20°C until assayed. clearance. The area under the serum concentration-time curve
The patients were kept in the Clinical Research Center for 48 hr (AUC) was calculated using the trapezoidal rule with C =R + S
after each dose of aztreonam for observation and collection of at t = 0.
biological specimens. Clearance by hemodialysis. Clearances of aztreonam and
Assay. Specimens of serum, urine, and dialysate were as- endogenous urea by hemodialysis, CLhd, were determined from
sayed by an agar-diffusion microbiologic technique using Esch- serum and dialysate concentration data for each patient using
erichia co/i strain SC12155 as the indicator organism as previ- each 1-hr period of collection of hemodialysis fluid. Methods A,
ously described [7, 81. This method has been shown previously B, and C were used to calculate clearance by hemodialysis [11,
to be comparable to an HPLC method for determination of 121:
aztreonam levels in serum and urine. Serum samples and
standards prepared in pooled human serum were initially dilut-
ed 1:20 in 0.1 M phosphate buffer (pH 6). A diluent of 5% serum
and 95% buffer was used for subsequent dilutions to test levels
QdCdCLI1dA =
c (3)SI
of 0.45 to 3 rg/ml. Specimens containing less than 0.45 zg/ml
were extracted with methanol and centrifuged, and the superna- (4
tant was diluted with buffer. Standards were prepared in the
buffer for the assay of urine specimens. All samples were
studied within 3 weeks of collection. The quantitation limits for (5)
aztreonam in serum, urine, and dialysate were 0.04, 0.1, and 0.2
g/ml, respectively. The specificity and precision of the assay where Qd was the dialysate flow rate, Qb was the blood flow
were shown by negative results for drug-free specimens and by rate, Cd0 was the spot concentration of effluent dialysate, C51
coefficients of variation of 3 to 5%. was the concentration in serum entering dialyzer, C50 was the
Pharmacokinetic analysis. Serum aztreonam concentration concentration in serum leaving dialyzer, H was the hemotocrit,
data from hemodialysis patients after dosing during the interdia- Ahd,1_5 was the total amount of compound collected in dialy-
lytic period were analyzed using a standard open, two-compart- sate during the 4-hr dialysis treatment conducted between 1 and
ment model [9]. Because aztreonam was infused over 2 mm, the 5 hr after administration of aztreonam, and serum AUChdl_5
exponential equation, C = Re_Ot + Se_at, a > /3, was used to was the area under the serum concentration versus the time
express the serum concentration (C, g/ml) versus time (t, hr). curve during hemodialysis from 1 to 5 hr after the administra-
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tion of doses. It should be noted that all concentrations and
flows for clearance calculations by methods A and B were those
determined at specific time points; 1, 2, 3,4, and 5 hr after drug
administration (or 0, 1, 2, 3, and 4 hr after start of dialysis).
Ahdi_5 was determined using
Ahdl_s = (Vhd)i(Chdcum)i
where (Vhd) was the total volume of hemodialysis fluid collect-
ed during the ith 1-hr collection, and (Chdcum)i was the concen-
tration in that 1-hr collection of dialysate.
The dialyzability of aztreonam in relation to urea [13] was
expressed as:
Az CLhd
x 100
urea CLhd
using clearance values obtained during hemodialysis by meth-
ods A, B, and C, described previously.
The serum half-life of aztreonam during hemodialysis was
compared to that during the interdialytic period using each
patient as his/her own control. In addition, the theoretical
amount of drug removed from the body by hemodialysis,
Ahd,theo.l_5, was calculated using:
(ti!2
off hd — t/2 on hd ) x
[I
— e
(_o.693Thd)]
X Dose (8)
off hd t1/2 hd
where t1/2 off hd and t112 hd were the serum half-lives of
aztreonam during the post-distributive phase off and on hemodi-
alysis, respectively, and Thd was the duration of hemodialysis
[141, In using the preceding equation, it was assumed that the
amount of drug eliminated during the 1 hr between dosing and
initiation of hemodialysis was negligible, a reasonable assump-
tion given the very long elimination half-life of aztreonam in
these patients during the interdialytic period.
Clearance by CAPD. Clearances of aztreonam given intrave-
nously and endogenous urea by peritoneal dialysis, CLd, were
determined from serum and dialysate concentration data for
each patient using the following relationship [15]:
—
(Ad8)I.V.CLd (serum AUCds).
where (serum AUCdg) was the area under the serum
concentration versus time curve from 0 to 48 hr after intrave-
nous administration of the drug, and (Ad8)I was the
amount of compound recovered in peritoneal dialysis fluid from
0 to 48 hr after intravenous dosing. (Ad,s)IV, was determined
using:
(Ads)V = (VP) (Cpd,cum)i
where (Vd)I was the total volume of peritoneal dialysis fluid
drained at the end of the ith 6-hr dwell time, and (Cpdcum)i was
the concentration in that 6-hr collection of dialysate. The
clearance of serum aztreonam by routes other than renal
elimination and peritoneal dialysis was calculated using
CLother = CLserum — CLrenai — CLd. (11)
The penetration of intravenous aztreonam into peritoneal dialy-
sis fluid was defined as
(pd AUCd,os).V.
(6) x 100 (12)(serum AUCds)t
where (pd AUCPd8)I was the area under the pentoneal
dialysate concentration versus time curve from time 0 to 48 hr
after an intravenous dose of the drug.
The dialysability of intravenous aztreonam in relation to urea
was expressed as described above using clearance values
obtained after an intravenous dose of aztreonam. The bioavail-
ability, Bio, or fraction of dose available to the systemic
(7) circulation, of intraperitoneal aztreonam was determined by
two methods [16]:
—
(serum AUCds)PB10A — (13)(serum AUCds)IV
BioB = i.p. dose — (Ad)1 (14)i.p. dose
where (serum AUCds)I was the area under the serum
concentration versus time curve from 0 to 48 hr after an
intraperitoneal dose, (serum AUCds)IV was the area under
the serum concentration versus the time curve after an intrave-
nous dose, i.p. dose was the intraperitoneal dose of aztreonam,
and (Ad) was the amount of drug recovered in dialysate
drained at 6 hr after an intraperitoneal dose.
Results
Hemodialysis. The mean serum levels for aztreonam in the
interdialytic period, arterial and venous serum concentrations
on dialysis, and the concentration in spot samples of dialysate
are provided in Table 2 and Figure 1. During the interdialytic
period, the maximum mean serum concentration was 117.5
g/ml (measured at the first sampling time of 10 mm after
aztreonam dosing); at 6 hr, levels were 37.7 sgIml and at 48 hr
they were 2.54 g/ml. At the start of hemodialysis, that is, 1 hr
after the dose of aztreonam, the mean level was 59.1 gIml in
arterial samples, comparable to 72.4 g/ml observed in 1-hr
(9) samples obtained in the interdialytic period. As anticipated,
there were decreasing arterial and venous levels of aztreonam
during the 4-hr hemodialysis period, with mean levels after the
fourth hour being 20.3 g/ml in arterial samples and 16.6 tg/ml
in venous samples; levels in the spot dialysate fluid also slowly
decreased during this period of time.
Table 3 presents the individual and mean values of the
pharmacokinetic parameters in patients off hemodialysis. For
reasons that are unclear, patient 1 had a markedly prolonged
serum elimination phase, resulting in a mean ti,2 for the group
(10) of 7.94. Omitting the data from patient 1 gave a mean value of
5.44. The serum concentration-time curves during the interdia-
lytic period were biphasic, suggesting an open, two-compart-
ment kinetic model. The rate of distribution of aztreonam was
described by ti/2a, k12, and k,1, which had mean values of 0.18
hr, 3.90 hr, and 1.95 hr, respectively. The extent of
distribution was represented by V1, V2, and Varea, which
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Arterial Venous Cone in spot
Serum cone serum conc serum conc samples of
interdialytic during during hemodialysis
•Time
hr
period
—
hemodialysis hemodialysis fluid
/sgIml
0 0.0 0.0 — 0.0 0.0 —
0.17 117.5 16.9 — — —
0.33 90.1 9.2 — — —
0.50 82.1 7.9 — — —
1 72.4 6.6 59.1 6.7 57.6 11.1 0.0 0.Oa
2 61.7 7.0 45.4 4.5 34.5 2.7 4.44 0.68
3 — 34.0 3.2 26.4 2.1 2.93 0.27
4 — 27.4 3.1 20.6 2.0 2.04 0.30
5 — 20.3 2.6 16.6 1.7 1.52 0.16
6 37.7 4.1 — — —
12 20.5 4.1 — — —
24 8.54 5.05b — —
36 8.54 7.16b — —
48 2.54 2.28b — —
a Values are the mean SEM for six patients studied both during
hemodialysis and the interdialytic period.b The 24, 36, and 48-hr values for subject 1 were 33.6, 44.3, and 9.35
JLg/ml, respectively. Excluding these three values in the calculations
would give 3.52 0.75, 1.38 0.46, and 0.28 0.28 g/ml at 24, 36,
and 48 hr, respectively.
Excluded is the 1-hr value of 4.39 for subject 5, which was
presumably obtained incorrectly, that is, after the start of hemodialysis.
had mean values of 0.10, 0.12, 0.21, and 0.22 liters/kg, respec-
tively. The rate of elimination of aztreonam was reflected by
t112 and k10, which had mean values of 7.94 hr and 0.31 hr,
respectively. The extent of elimination of aztreonam was re-
flected by the mean urinary recovery 1.97% of the dose (three
of six patients provided urine specimens). The mean serum,
renal, and other clearances of aztreonam were 24.4, 0.5, and
23.9 mI/mm, respectively. Serum clearance of aztreonam was
primarily by non-renal mechanisms.
A mean of 38.2% of a 1-g dose of aztreonam was recovered in
dialysis fluid (Table 4); this figure agreed well with the theoreti-
cal amount of aztreonam eliminated by hemodialysis (3 8.6% of
the dose). The mean clearance by hemodialysis according to the
three methods of calculation ranged from 36.6 to 43.2 mi/mm,
and was approximately 50 to 77% greater than the serum
clearance of aztreonam during the interdialytic period (24.4
ml/min, Table 3). Similarly, the mean elimination half-life
during hemodialysis (2.67 hr) was approximately one-third that
during the interdialytic period (7.94 hr). The mean amount of
urea recovered in dialysis fluid was 16,539 mg, and the mean
clearance of urea by hemodialysis ranged from 112.4 to 155.6
mI/mm for the three methods of calculation. During hemodialy-
sis, the mean aztreonam clearance was 28 to 33% of the mean
urea clearance.
CAPD. Mean serum and dialysate concentrations after intra-
venous administration of aztreonam are given in Table 5 and
Figure 2. The maximum mean serum concentration (measured
at the first sampling time of 10 mm after the dose was given) was
204 jig/mI. This value was approximately half the initial az-
treonam concentration in dialysis fluid (500 jig/mI), probably
due to the combined effects of (1) rapid distribution into
extraperitoneal tissue (via the systemic circulation in a manner
similar to the cs-phase after intravenous dosing, and (2) dilution
with residual, undrained dialysis fluid (consisting perhaps of
several hundred milliliters).
Aztreonam was detected in serum for 48 hr after the dose was
administered. The average concentration of aztreonam in pen-
toneal dialysis fluid reached a maximum mean value of 20.8
jig/mi at 6 hr postdosing, just prior to the first postdose
exchange of dialysis fluid. Although dialysis fluid was ex-
changed with fresh fluid at 6-hr intervals, aztreonam was
measurable in dialysate for up to 48 hr postdosing.
Mean serum and dialysate concentrations of aztreonam after
intraperitoneal dosing are given in Table 6 and Figure 3. The
maximum mean dialysate concentration (measured at the first
sampling time, 10 mm postdosing) was 274 jig/nil. At 6 hr
postdosing, the mean dialysate concentration was 104.8 jig!ml.
Thereafter, dialysis fluid was exchanged at 6-hr intervals, and
mean concentrations at 12 to 48 hr postdosing were 11.7 to 0.2
jig/ml, respectively. The average concentration of aztreonam in
serum reached a maximum value of 30.0 jig/ml at 6 hr postdos-
ing (time of first exchange), and declined thereafter to 0.4 jig/mi
at 48 hr postdosing.
The aztreonam serum concentration-time curves for individ-
ual CAPD patients after intravenous administration of az-
treonam were biphasic, suggesting an open, two-compartment
kinetic model. Pharmacokinetic parameters for each patient
after intravenous dosing are given in Table 7. The rate of
distribution of aztreonam was described by tI/2a, k12, and k21,
which had mean values of 0.19 hr, 5.26 hr', and 0.93 hr,
respectively. The extent of distribution was represented by VI,
V2, and Varea, which had mean values of 0.06, 0.11, 0.16,
and 0.19 liters/kg. The rate of elimination was reflected by t112
and k10, which had mean values of 7.08 hr and 1.57 hr,
respectively. The extent of elimination of aztreonam was re-
flected by the mean urinary recovery, 1.93% of dose (two of six
patients provided urine specimens), and mean dialysate recov-
Table 2. Mean serum concentrations of aztreonam during
hemodialysis and the interdialytic period (l-g doses)a
1000
100
40 50
Time after dosing, hours
Fig. 1. Mean concentrations of aztreonam in serum after a 1-g iv.
infusion of antibiotic over 2 mm in patients during hemodialysis (solid
circle) and in the interdialytic period (open circle).
10 20 30
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Table 3. Individual and mean values of pharmacokinetic parameters during interdialytic period (1-g i.v. dose of aztreonam) in hemodialysis
patients
Patient number
Parameter 1 2 3 4 5 6 Mean SEM
t1/2, hr 0.08 0.13 0.05 0.29 0.27 0.27 0.18 0.04
t112, hr 20.39 4.75 6.19 4.95 4.85 6.48 7.94 2.SIa
k12, hr 7.01 1.80 12.2 0.84 0.72 0.81 3.90 1.93
k21, hr1 0.98 3.46 2.23 1.48 1.78 1.75 1.95 0.35
k10, hr' 0.29 0.23 0.76 0.23 0.21 0.16 0.31 0.09
V1, liters/kg 0.04 0.13 0.03 0.10 0.14 0.15 0.10 0.02
Vsc, liters/kg 0.32 0.19 0.19 0.16 0.20 0.22 0.21 0.02
V2, liters/kg 0.28 0.07 0.16 0.06 0.06 0.07 0.12 0.04
Vara, liters/kg 0.33 0.20 0.20 0.17 0.21 0.23 0.22 0.02
Rec. 0 to 48 hr urine, % dose 0 0 0 4.36 4.30 3.15 1.97 0.90
CL,m, ml/min 7.81 23.7 34.4 26.00 35.20 19.40 24.40 4.20
CLrnai, mI/mm 0 0 0 1.10 1.50 0.60 0.50 0.30
CLoihar, mi/mm 7.81 23.7 34.4 24.90 33.70 18.80 23.90 4.0
AUC8, p.g X hr/mI 1,953.50 742.8 497.4 681.10 505.40 876.50 876.10 223.4
a The value calculated by omitting patient 1 was 5.44 0.37 hr.
Table 4. Individual and mean values of pharmacokinetic parameters during 4 hr of hemodialysis (1-g i.v. dose of aztreonam)
Patient number
Parameter 1 2 3 4 5 6 Mean SEM
Aztreonam
Rec. by HD, % dose 57.7 42.0 26.7 33.0 31.2 38.5 38.2 4.5
CL5dA, ml/minc 47.1 40.8 40.4 43.8 44.0 39.2 42.6 1.2
CLSdB, ml/min 40.7 37.1 35.2 36.5 27.4 42.8 36.6 2.2
CLhdc, mI/mm 49.7 41.5 41.0 40.5 46.1 40.1 43.2 1.6
t112 on HDb, hr 3.15 1.87 3.30 1.87 2.42 3.41 2.67 0.29
11/2 off HD, hr 20.39 4.75 6.19 4.95 4.85 6.48 7.94 2.510
Theoretical amount removed
by HD, % dose 49.5 46.9 26.5 48.1 34.2 26.4 38.6 4.4
Urea
Recovered by HD, mg 15,702 12,347 15,047 22,775 20,030 13,334 16,539 1652
CLSdA, mI/mm 142.0 151.8 135.2 178.5 174.9 151.5 155.6 7.1
CLSdB, mI/mm 90.4 114.9 109.0 118.9 126.1 115.2 112.4 5.0
CLhdC, mI/mm 139.9 147.5 136.7 177.4 173.9 155.4 155.1 7.0
(Az.CLhd/Urea CLhd) x 100
Method Ac 33.2 26.9 29.9 24.5 25.2 25.9 27.6 1.4
Method B 45.0 32.3 32.3 30.7 21.7 37.2 33.2 3.1
Method C 35.5 28.1 30.0 22.8 26.5 25.8 28.1 1.8
a The value calculated by omitting patient 1 was 5.44 0.37 hr.
This was based on aztreonam concentration in arterial serum.
See Methods for a description of methods A, B, and C used in the calculation of parameters listed above.
ery, 9.74% of the dose. The mean serum, renal, peritoneal
dialysis, and other clearances were 23.8, 0.5, 2.1, and 21.3
mi/mm, respectively. The mean ratio of dialysate AUC to
serum AUC after intravenous dosing was 35.6%, an index for
penetration into the peritoneal fluid.
The mean clearance of urea from plasma by peritoneal
dialysis after intravenous administration of aztreonam was 6.52
mllmin, and the mean amount of urea recovered in dialysate
was 13,876 mg. The mean aztreonam clearance by CAPD was
32.0% of the mean urea clearance by CAPD.
The bioavailability of intraperitoneal aztreonam according to
two methods of calculation is reported in Table 8. Based on the
ratio of serum AUC after an intraperitoneal dose to serum AUC
after an intravenous dose, the mean bioavailability to the
systemic circulation was 59.4%. Based on the intraperitoneal
dose and the amount of unabsorbed aztreonam drained from the
peritoneal cavity, the mean bioavailabiiity was 72.9%. The
latter value could have been an overestimate of systemic
bioavaiiability, if significant amounts of aztreonam-containing
dialysate were retained in the abdominal cavity, or if aztreonam
absorbed by the portal venous system was partially cleared by
hepatic elimination.
Single intravenous and intraperitoneal doses of aztreonam
were tolerated well by all hemodialysis and CAPD patients; no
adverse reactions or notable changes in laboratory test values
were found.
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Table 5. Mean concentrations of aztreonam in serum and peritoneal
dialysis fluid in CAPD patients (1-g iv. dose)
Time after Serum conc,a Dialysate conc,a
dosing, hr g/ml jsglml
o o.o 0.0 0.0 0.0
0.17 204 58 4.26 1.62
0.33 93.7 8.0 7.15 2.57
0.5 77.9 8.9 7.20 1.98
64.5 3.3 12.71 2.96
2 53.5 5.0 16.56 3.25
3 — 17.76 3.33
4 — 19.25 2.95
6 32.8 1.4 20.78 2.92
12 17.7 1.5 8.44 0.77
18 — 4.82 0.56
24 5.90 1.83 2.70 0.62
30 — 1.52 0.46
36 2.40 1.91k 0.87 0.48
48 0.82 0.71 0.27 0.23
The values are mean SEM for six patients.
The calculated mean excludes 14.0 sg/ml value for patient 12,
because this value was more than fourfold greater than his 24-hr value.
0
Fig. 2. Mean concentrations of aztreonam in serum (circle) and
dialysate (triangle) after a 1-g, 2-mm, iv. infusion in six CA PD patients
(dwell-time 6 hr).
Table 6. Mean concentrations of aztreonam in serum and peritoneal
dialysis fluid in CAPD patients (1-g i.p. dose)
Dialysate conc,a
.sg/ml
0.0 0.0
274
310
304
260
200
166.7 11.4
— 140.8 10.3
30.0 3.3 104.8 13.4
18.2 4.1 11.72 1.50
— 4.28 0.47
3.96 0.82 1.99 0.29
1.02 0.35
0.50 0.26
0.17 0.14
4
6
12
18
24
30 —
36 1.07 0.63
48 0.43 0.38
a The values are mean SEM for six patients.
Time after dosing, hours
Fig. 3. Mean concentrations of aztreona,n in serum (circle) and
dialysate (triangle) after a 1-g i.p. dose in six CAPD patients (dwell-time
6 hr).
Time after
dosing, hr
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Discussion
Aztreonam has a wide spectrum of in vitro activity against
gram-negative aerobic bacteria. It is likely that it will receive
extensive use in very ill patients, some of whom will be
supported acutely and chronically by hemodialysis and CAPD.
In addition, the beta-lactam aztreonam would have a notable
safety advantage compared to aminoglycosides in ESRD pa-
tients, who would be at risk of aminoglycoside-induced ototoxi-
city. A knowledge of the pharmacokinetics of aztreonam in this
type of patient will be extremely important for the proper use of
the drug. In the present study, pharmacokinetics of aztreonam
were investigated in hemodialysis and CAPD patients in a
crossover study using volunteers with ESRD supported by
regular dialysis. These patients were representative of our
dialysis population and all were dialyzed under essentially
identical conditions using routine techniques. The mean serum
clearance of aztreonam after intravenous administration during
the interdialytic period in hemodialysis patients was 24.4
mI/mm, which corresponded closely to the mean value of 29
ml/min for a similar group of patients taking part in a previous
study [71. In contrast, the mean serum clearance of aztreonam
in healthy subjects is approximately 107 mI/mm [71. The mean
interdialytic elimination half-life in the present study was 7.94
hr, also similar to the previously reported value of 6.02 hr [71. In
contrast, the mean serum half-life of aztreonam in healthy
subjects is 1.7 to 2.9 hr [6, 71.
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Table 7. Pharmacokinetic parameters for aztreonam in six CAPD patients (I-g i.v. dose)
Patient number
Patient 1 in the current study had an apparent interdialytic
elimination half-life of 20.4 hr, suggesting an important defect in
non-renal elimination, inasmuch as the other five patients had
mean half-lives in the range of 4.75 to 6.48 hr. Patient 1 was
unique in having bilateral amputation of the lower extremities.
However, no clear explanation for the significantly impaired
elimination in this patient is presently available.
The clearance of aztreonam during hemodialysis was deter-
mined by three methods: method A, based on dialysate flow
rate; method B, based on estimated plasma flow rate; and
method C, based on the amount of drug in the cumulative
dialysis fluid. Method B required an estimate of plasma flow
rate, calculated using hematocrit and blood flow rate, two
possible sources of measurement error. In addition, this method
would underestimate clearance, if aztreonam binds to or enters
red blood cells to a significant extent. (Such phenomena can
theoretically be represented by replacing (1 — H) with (1 — H +
KH) in the equation for CLhd,p where K is the ratio of drug
concentration in red cells to concentration in plasma; however,
K was not measured in this study.) In contrast, dialysate flow
rate (method A) and the total amount of drug collected in
dialysate (method C) were determined over 1- to 4-hr time
intervals, and would be somewhat less susceptible to random
sources of measurement error. Method C would appear to be
the method of choice, because it is based on direct measure-
ment of the total amount of drug cleared by dialysis.
The ratio of aztreonam to urea clearance by hemodialysis was
approximately 0.3, indicating that aztreonam is not cleared as
Parameter 3 4 5 6 Mean SEM
0.37
5.17
0.64
1.16
0.22
0.11
0.17
0.06
0.18
0
11.50
22.7
0
2.43
20.3
0.06
14.1
8.88
0.18
3.39
0.003
0.16
0.15
0.22
0
10.83
13.3
0
1.52
11.8
0.04
7.00
12.4
0.41
4.07
0.005
0.14
0.14
0.19
0
8.63
21.5
0
1.68
19.8
Aztreonam
t12,hr
t1 , hr
k12, hr
k21, hr
k10, hr
V1, liters/kg
V, liters/kg
V2, liters/kg
Varea, liters/kg
Rec. 0—48 hr urine, % dose
Rec. 0—48 hr dialysate, % dose
CLserum, mI/mm
CLrenai. mi/mm
CLd, mi/mm
CLother, mi/mm
SerumAUCd, 0—48, g X hr/ml
pdAUCPd, 0—48, .rg X hr/mi
(pdAUCds)
(serumAUCd.)
Urea
Rec. 0—48 hr dialysate, mg
AUCserum, mg x hr/mi
CLd, mi/mm
(Az.CLPd)
><
(urea CLd)
0.07
5.42
7.80
0.98
1.30
0.02
0.16
0.14
0.18
7.94
11.81
26.2
2.08
2.92
21.2
0.36
5.64
0.80
1.03
0.23
0.10
0.18
0.08
0.19
1.70
5.52
29.6
0.50
1.24
27.9
0.24
5.17
1.01
1.81
0.21
0.12
0.18
0.07
0. 1
10.15
29.5
2.83
26.7
0.19
7.08
5.26
0.93
1.57
0.06
0.16
0.11
0.19
1.93
9.74
23.8
0.5
2.10
21.3
0.06
1.43a
2.08
0.24
0.71
0.02
0.01
0.02
0.01
1.40
0.96
2.5
0.4
0.29
2.4
789.4 1188.7 855.8 672.9 742.7 598.2 808.0 84.5
354.0 277.1 240.4 357.0 167.1 250.7 274.4 29.7
44.8 23.3 28.1 53.0 22.5 41.9 35.6 5.2
9,381 9,344 29,572 5,233 13,839 15,886 13,876 3,492
24.2 24.5 71.5 13.5 40.8 36.2 35.1 8.3
6.46 6.36 6.89 6.46 5.65 7.31 6.52 0.23
37.6 23.9 24.4 45.2 21.9 38.7 32.0 4.0
a Excluding patient 2, the calculated mean is 5.68 0.34.
b Aztreonam was measurable in urine; however, volumes of urine collections were not recorded.
Table 8. Bioavailability of intraperitoneally administered aztreonam in six CAPD patients (l-g dose)
Patient number
Parameter 1 2 3 4 5 6 Mean SEM
(serumAUCd€S) i.p., jig x hr/mi 534.0 426.2 330.3 692.0 362.0 376.6(serumAUCdS) i.v., jig x hr/mi 789.4 1188.7 855.8 672.9 742.7 598.2
BioA, % of dose 67.6 35.8 38.6 102.8 48.7 63.0
453.5 55.8
808.0 84.5
59.4 10.1
(VPd)6, mi 2,470 (2,200) 2,735 2,315 3,015 3,155
(Cpdcum)6, jig/mI 86.8 170.0 98.3 98.7 79.3 95.4
APd,, mg 214.4 374.0 268.8 228.4 239.1 301.0
BioB, % of dose 78.6 62.6 73.1 77.2 76.1 69.9
—
—
—
72.9 2.4
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Table 9. Comparison of pharmacokinetics of aztreonam with other beta-lactam antibiotics in hemodialyzed patients
Antibiotic
Clearance, mi/mm Fraction of dose Elimination half-life, hr
removed by
Interdialytic During hemodialysis Interdialytic During
Dose Route period dialysis (duration of HD) period dialysis Reference
Aztreonam
Moxalactam
Cefotaxime
Cefoperazone
Ceftizoxime
Cefsulodin
Ceftazidime
Cefoxitin
Cefamandole
Cefonicid
Cefazolin
Cephalexin
Cephalothin
Piperacillin
I g i.v. 24.4 43.2 0.38 (4 hr) 7.9 2.7
1 g iv. 12.8 43.6 0.48 (4 hr) 18 2.7
1 g i.v. — — — 2.7 1.2
2 g i.v. — — 0.12 (4.5 hr) 2.2 2.2
Not given Not given — — — 29 4.9
1 g i.v. — — 0.45 (6 hr) — —I g iv. — — — 27 4.5
30 mg/kg i.v. — — — 21.6 3.7
1 g i.v. — — — 8.0 6.2
7.5 mg/kg iv. 1.79 3.4 0.10 (4 hr) 50.7 —
0.5 or 1 g i.v. or i.m. — — — 39.8 6 to 14
1.Sg iv. — — — 18.2 —
0.25 or 0.5 g p.o. — — — — 3.6
I g i.v. — — — 2.8 3.3
1 g i.v. — 8.1 0.11 (4 hr) — 3.7
Present study
[121
[171
[17]
[17]
[17]
[17]
[181
[191
[201
[19]
[19]
[19]
[19]
[21]
Table 10. Comparison of pharmacokinetics of aztreonam with other beta-lactam antibiotics in CAPD patients
Antibiotic
Clearance, Elimination % Of iv. dose
m1 mm half-life, hr recovered in PD
fluid Bioavail of
Dose Route Serum By PD Off PD On PD (duration of PD) i.p. dose, % Reference
Aztreonam
Moxalactam
Cefotaxime
Cefoperazone
Ceftizoxime
Cefuroxime
Cefoxitin
Cefamandole
Cefazolin
I g i.v. 23.8 2.la — 7.1 9.7 (48 hr) —I g i.p. — — — — — 66
1 g iv. — — 18.1 19.2 4.9 (24 hr) —
Not stated i.v. — — 4.4 2.9 — —
2 g i.v. — — — 2 — —
200 g/ml i.p. — — — — — 75
3 g iv. 17.1 2.8k' — 12.5 — —
0.5 g i.v. — — — 5.1 to 20.8 15(6 hr) —
0.5 g i.p. — — — — — 86
15 mg/kg i.v. — 4.18 — 14.7 — —
0.5 g i.v. 15.8 4.7 — 11.8 20.0 —
2 g iv. 20.4 1.44 — 7.8 — —I g i.v. — — — 7.2 — —
0.5 or 1 g i.v. — — — 32.5 19 —
10mg/kg i.v. 5.70 1.04 — — — —
10mg/kg i.p. 5.85 0.81 — — — 74
Present study
Present study
[22]
[23]
[24]
[24]
[25]
[26]
[26]
[27]
[28]
[29]
[30]
[31]
[31]
[31]
a The peritoneal clearance of urea was 6.5 mI/mm.
b The peritoneal clearance of urea was 5.0 mI/mm.
well as urea during hemodialysis. This is reasonable, given the
much larger molecular size of aztreonam (molecular weight
435.4) compared to urea (molecular weight 60), and the result-
ing lower permeability of such a molecule. The comparison of
concurrently measured aztreonam and urea clearances suggests
a more general interpretation of the results of the present study;
that is, for other hemodialysis equipment and operating condi-
tions, aztreonam might be expected to be cleared about 30% as
well as urea. The pharmacokinetics of aztreonam during hemo-
dialysis are compared with those of other beta lactam antibiot-
ics in Table 9 [12, 17—211. (No reports of concurrently measured
antibiotic and urea clearance by hemodialysis were found.)
Hemodialysis consistently reduces the elimination half-life of
these antibiotics, as would be expected, because they are
dialysable. Clearance of aztreonam was most similar to that of
moxalactam,
The clearance of aztreonam by CAPD (mean, 2.10 mL/min)
was only about 5% of its clearance by hemodialysis (mean
range, 36.6 to 43.2 mllmin). Similarly, the clearance of urea by
CAPD (mean, 6.52 ml/min) was approximately 5% of the
clearance of this substance by hemodialysis (mean range, 112.4
to 155.6 ml/min). The slower rate of urea clearance during
CAPD is compensated for by the continuous nature of CAPD
therapy. Clearance of aztreonam by CAPD was similar to that
of ceftizoxime (Table 10 [22—311). For aztreonam as well as the
other beta-lactam antibiotics listed, CAPD clearance was typi-
cally a small fraction of serum clearance. Consistent with this
finding is the observation that only a small fraction of an
intravenous dose of various beta-lactam antibiotics is recover-
able in peritoneal dialysate. In one study, in which urea and
ceftizoxime clearances were determined simultaneously during
CAPD, the antibiotic/urea clearance was 2.8/5.0 = 0.56 [251,
compared to 2.1/6.5 = 0.32 for aztreonam. Some of the appar-
ent kinetic differences between antibiotics may be due to
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differences in dialysis equipment and procedures at various
medical centers.
Although aztreonam movement across the peritoneal mem-
brane was bidirectional, comparison of the 60 to 70% bioavail-
ability of intraperitoneally administered drug with the 10%
recovery in peritoneal dialysate of intravenously administered
drug suggests that transfer from peritoneal fluid into blood is
much more efficient than from blood into peritoneal fluid. The
beta-lactams cefazolin and ceftizoxime demonstrate a similar
phenomenon (Table 10). Transport of gentamicin from blood to
peritoneal fluid is also very slow compared to transport in the
opposite direction, such that an intravenously administered 1-
mg/kg dose may not produce detectable gentamicin levels in
peritoneal dialysate [16]. While the fundamental mechanism for
this phenomenon is unclear, these findings may nevertheless be
clinically significant. Intraperitoneal administration of az-
treonam is more efficient than intravenous administration in
producing therapeutic levels of aztreonam in peritoneal fluid
and should, therefore, be evaluated in the therapy of bacterial
peritonitis due to susceptible organisms.
Results of the present study lead us to propose the following
adjustment of aztreonam dosage in patients supported by
hemodialysis and CAPD. Hemodialysis patients and CAPD
patients with infections other than peritonitis should receive an
intravenous loading dose equal to the standard dose in patients
with normal renal function, followed by periodic intravenous
doses that are equal to
Doseu = [i] x Doses, (15)
where DoseN and Doseu are the doses of aztreonam in patients
with normal renal function and renal insufficiency, respectively,
and CLN and CL are serum clearances of aztreonam in
patients with normal renal function and renal insufficiency,
respectively. We previously showed [7] that CLN = 101.3
mllmin. From Table 3, CLu = 24.4 mL/min for hemodialysis
patients during the interdialytic period, and from Table 7, CL
= 23.8 ml/min for CAPD patients. Therefore, for both catego-
ries of dialysis patients, Doseu = (241101)DoseN, or approxi-
mately 25% of the standard dose, which agrees with guidelines
previously published for patients with severe renal disease
(creatinine clearance less than 10 mllmin). In addition, hemodi-
alysis patients should receive a supplemental dose of aztreonam
alter hemodialysis to compensate for the antibiotic removed by
hemodialysis (38%, range 27 to 58%, of a l-g dose). The
supplemental dose should be half the pre-dialysis adjusted
maintenance dose.
For example, if the standard treatment regimen for patients
with normal renal function is 1 .0-g i.v. aztreonam every 8 hr,
hemodialysis or CAPD patients similar to those in the present
study should receive a 1-g i.v. loading dose followed by 0.25 x
1.0 = 0.25 g i.v. every 8 hr. In addition, after hemodialysis a
patient should receive a supplemental intravenous dose of 0.5 x
0.25 g, or 0.125 g, before continuing with the previously
scheduled treatment regimen (0.25 g every 8 hr).
Since a 1 .0-g i.v. dose of aztreonam produces a mean peak
peritoneal dialysate concentration of only 21 pg/ml in peritoneal
dialysate 6 hr after the dose has been administered, it may not
be advisable to attempt to treat peritonitis with aztreonam
solely by this route. CAPD patients with peritonitis caused by
organisms sensitive to aztreonam can be given the antibiotic in
the pentoneal dialysate fluid, as was done in the current study.
This will insure high local levels of antibiotic. A l.0-g dose of
aztreonam in 2 liters of dialysate produced a peak measured
concentration of about 300 g/m1, which declined to 105 sg/ml
alter the 6-hr dwell time. The M1C90 for Enterbacteriaceae is
approximately 1 g/ml, and for Pseudomonas aeruginosa is
approximately 12 g/ml. Therefore, it is reasonable to use 0.5 g
i.p. in 2 liters of dialysate every 6 hr, which should produce a
peak level of about 150 g/ml, and a 6-hr level of about 50
g/ml. Due to the lag in equilibration of aztreonam between
dialysate and serum after intraperitoneal administration, it
would also be appropriate to administer a 1 .0-g i.v. loading dose
at the initiation of antibacterial therapy.
Alternatively, intraperitoneal administration as therapy for
systemic (non-peritoneal) infections would decrease cost, in-
crease convenience, and avoid the risks of intravenous cathe-
ters. Although a short delay in absorption occurs after initial
intraperitoneal administration, this may be of little clinical
significance. Assessment of the patient's clinical status should
dictate any necessity for a loading dose prior to intraperitoneal
dosing.
It is important to remember that the dosimetry recommenda-
tions for peritonitis have been developed from data in non-
infected subjects. Because peritonitis may be associated with
significantly increased urea and creatinine clearance [321, the
patient with peritonitis may have aztreonam kinetics somewhat
different from those reported here, although some studies have
demonstrated little effect of peritonitis upon kinetics [16]. Until
direct data on aztreonam kinetics in peritonitis are available,
measurement of antibiotic levels or, alternatively, urea and
creatinine, should provide necessary dosimetry information in
the individual patient with bacterial peritonitis.
Although approximately 10 to 40% of the cases of peritonitis
in CAPD patients are due to aerobic gram-negative bacteria
sensitive to aztreonam [33, 341, peritonitis in CAPD patients is
often due to gram-positive organisms. These organisms are
generally considered to be resistant to aztreonam (MIC's typi-
cally > 100 jg/ml). Therefore, initial therapy of peritonitis in
CAPD patients should provide antibacterial coverage for both
gram-positive and gram-negative bacteria. The compatibility
and stability of peritoneal dialysis solutions of aztreonam and
other antibiotics must be assured before attempting concurrent
intraperitoneal therapy [35]. -
In conclusion, the present study confirms our previous
findings of the effect of ESRD on the kinetics of intravenous
aztreonam. The results of those studies have been extended by
examining aztreonam kinetics in similar hemodialysis patients
during both dialysis and interdialytic periods and in CAPD
patients. Urea and aztreonam clearances have been analyzed
simultaneously, allowing the determination of a ratio for esti-
mating the clearance of aztreonam from urea clearance for any
particular patient and dialysis system. This ratio should also
allow more precise comparison with clearances of other antibi-
otics whose kinetics are reported in relationship to urea clear-
ance. Single doses of aztreonam were safely administered to
patients with ESRD with no apparent side effects. Hemodialy-
sis had a significant effect on the pharmacokinetics of the drug.
Consequently, the aztreonam dosage regimen should be modi-
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fled for patients with severe renal insufficiency requiring sup-
port by hemodialysis. Aztreonam penetrates the peritoneal
membrane in a bidirectional fashion allowing intravenous or
intraperitoneal administration of the antibiotic to achieve de-
sired compartmental levels. However, less adjustment is need-
ed for CAPD, and utilization of the proposed dosage guidelines
should allow aztreonam to be safely and effectively adminis-
tered to patients on CAPD with infections due to susceptible
organisms.
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